---
author: mike
pubDatetime: 2024-05-02 19:40:11.706000
modDatetime: 
title: Q124 UTHR earnings
slug: q124-uthr-earnings
featured: false
ogImage: /assets/images/250_250.png
tags:
  - transcripts
  - earnings
description: Earnings summary for United Therapeutics
---
### Earnings Results
- **Organic Revenue Growth:** Achieved a 2% year-over-year increase.
- **Adjusted Operating Margin:** Improved by 290 basis points sequentially, reaching 33%.
- **Quarterly Revenue:** Grew by 3% to $303.4 million, with 1% of this growth attributed to acquisitions.
- **Adjusted EPS:** Declined to $0.48 from $0.53 in the same quarter of the prior year.
- **GAAP EPS:** Decreased to $0.31 from $0.43 year-over-year.
- **Adjusted Gross Margin:** Reported at 71.9%, a slight decline from 72.6% previously.
- **Operating Margin for Protein Sciences Segment:** Dropped by 90 basis points to 44.2% year-over-year.
- **Diagnostics and Genomics Segment Revenue:** Increased by 16% to $87.5 million, with a 10% organic revenue growth.

### Future Guidance
- **Q4 Expectations:** The company anticipates its performance to mirror Q3 levels, anticipating stable markets, especially in the biotech sector and China region.
- **Revenue and Margin Improvement:** Forecasts incremental sequential revenue and adjusted operating margin improvements in Q4 compared to Q3.
- **FY25 Outlook:** The company is closely monitoring the impact of increased biotech funding and Chinese government stimulus for adjustments to their fiscal year 2025 outlook and operating plans.

### Trends, Market Conditions, Sentiment
- **Market Stabilization:** Early signs suggest stabilization in the biopharma end markets and the China region, with expectations of improvement in the latter half of the year.
- **Challenge in China:** Although there's a recognition that returning to accelerated growth in China might be slower, there's confirmation of business stabilization there.
- **Growth Pillars Performance:** Noteworthy performance in areas such as cell and gene therapy, proteomic analysis solutions, spatial biology technology, and liquid biopsy platforms.
- **Cost Management:** The company remains focused on profitability through efficiency improvements while continuing to invest for future growth.
- **Future Growth Enablers:** The recovery in biotech funding and economic stimulus from the Chinese government are being closely monitored as potential drivers of future revenue growth.

### Notable Quotes
- _"I'm pleased to report that our third quarter outperformed our initial expectations..."_ - Kim Kelderman, President and CEO.
- _"These growth pillars enabled by our leading portfolio of proteomic reagents and assays remain and clearly well-positioned to enable our customers to improve the quality of life..."_ - Kim Kelderman.
- _"It appears as though the worst of the China slowdown is behind us at this point."_
- _"M&A remains a top priority for capital allocation."_ - James Hippel, CFO.
- _"...expect that gap in our performance relative to the market to be at least the same, if not better."_ - James Hippel on future growth relative to the market.
